News

Sagent Pharmaceuticals has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. Sagent will begin marketing and shipping vinorelbine injection immediately. Sagent’s vinorelbine injection is offered in 10mg per

Can-Fite BioPharma has initiated the preparatory work for a phase III trial with CF101 in psoriasis. This is based on the conclusion of a phase II dose-response clinical

Hospira has announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska. Filgrastim is a granulocyte colony-stimulating

Hana Biosciences has announced that the company has entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI)

Germany-based Merck has submitted a new drug application (NDA) to the FDA for Cladribine tablets, an investigational oral formulation of cladribine, as a therapy for reducing relapses in

Palatin Technologies will receive $5m from AstraZeneca relating to an amendment of its ongoing exclusive research collaboration and license agreement to discover, develop and commercialise compounds that target

ATMI has expanded its line of Newsafe contained Powder Transfer Bags with the introduction of bags fabricated with a new anti-static polymer film that increases the number of

Sepha, a blister packing, deblistering, and pharmaceutical leak testing company, commented that the pressure to reduce waste is raising demands for its Press-Out deblistering technologies, quotes in-Pharma. The

Lupin has acquired US rights for Antara (Fenofibrate capsules 43mg, and 130mg) for $38.61m from Oscient Pharmaceuticals. Lupin had filed an ANDA for fenofibrate capsules 43mg and 130mg.